Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia

anon79999497 · October 2, 2014, 6:46am

ncbi.nlm.nih.gov

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

SM Hosseini, M Farokhnia, F Rezaei, A Gougol, H Yekehtaz, N Iranpour, B Salehi, M Tabrizi, M Tajdini, A Ghaleiha and S Akhondzadeh, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, Jun 2014

Considering the role of neurohypophyseal peptides in normal development and function of higher cortical processes along with their proven abnormalities in schizophrenic patients, these pathways have recently attracted greater attention as treatment targets for schizophrenia. Desmopressin (DDAVP) is a synthetic analog of vasopressin. This study aimed to evaluate the efficacy and safety of DDAVP nasal spray as an adjunct to risperidone in improving negative symptoms of schizophrenia. In this randomized double-blind placebo-controlled clinical trial, forty patients aged 18-50 years with a DSM IV-TR diagnosis of chronic schizophrenia and a minimum score of 60 on positive and negative syndrome scale (PANSS) were equally randomized to receive DDAVP nasal spray (20mcg/day) or placebo in addition to risperidone for 8 weeks. Patients were partially stabilized and treated with a stable dose of risperidone (5 or 6mg/day) for at least four weeks prior to entry. Participants were rated by PANSS every two weeks and decrease in the PANSS negative subscale score was considered as our primary outcome. By the study endpoint, DDAVP-treated patients showed significantly greater improvement in the negative symptoms (P=0.001) as well as the PANSS total and general psychopathology subscale scores (P=0.005 and P=0.003; respectively) compared to the placebo group. Treatment group was the strongest predictor of changes in negative symptoms (β=-0.48, t=-3.67, P=001). No serious adverse event or fluid/electrolyte imbalance was reported in this trial. In conclusion, DDAVP nasal spray showed to be an effective and safe medication for improving negative symptoms in patients with chronic schizophrenia.

Skims · October 2, 2014, 8:22pm

Cool intranasal spray! Anything not to have to take another pill.

Topic		Replies	Views
Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial News	8	962	March 16, 2017
Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis News	1	527	November 10, 2016
Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial News	25	1009	December 14, 2016
Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials News	1	334	December 26, 2018
Risperidone and escitalopram co-administration: A potential treatment of schizophrenia symptoms with less side effects News	4	1088	October 20, 2016

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia

Related topics